2022 Revenues ($USD) : $322,825,000
2022 R&D spend : $38,671,000
2022 Number of Employees : 1,700
Fiscal Year End : 12/31/2021
Company CEO : Quentin Blackford, president and CEO

Seeking to usurp the old-school Holter monitor for electrocardiograph monitoring and AFib detection, iRhythm has developed the Zio XT platform. The wearable includes cloud-based data analytics and machine-learning capabilities for cardiac monitoring. Founded in 2008, the San Francisco–based company’s Zio service aims to offer quality clinical accuracy, positive patient experience and compliance. It also holds the promise of lower cost of care through the miniature, wearable patch that includes a breathable, waterproof outer layer and a strong adhesive with a flexible design for secure attachment on the left side of the chest. In 2022, the company continued to build its leadership team, hiring Dr. Mintu Turakhia as chief medical officer and chief scientific officer, Brice Bobzien as chief financial officer and Reyna Fernandez as chief human resources officer. Chief Commercial Officer Dave Vort resigned in July, replaced by Chad Patterson. – SW and JH